VEGFA and neoplasm: Both antibodies targeting the soluble form of VEGF and small tyrosine kinase inhibitors of VEGF receptors have shown anti-tumor activity, yielding a significant increase in progression free survival in several types of cancer including advanced renal cell carcinoma [4, 5], advanced hepato-cellular carcinoma [6], and metastatic colorectal cancer [7].